ArticleHepatology international2026
Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab-bevacizumab in hepatocellular carcinoma.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
background/purpose. Although atezolizumab-bevacizumab is approved for unresectable hepatocellular carcinoma (HCC), only a subset of patients attains a durable response (DR). Non-invasive predictors of long-term benefit are lacking. We aimed to assess whether baseline circulating cell-free DNA (cfDNA) quantity combined with cfDNA-derived genetic and methylation profiling could predict prognosis and DR.
methodsWe retrospectively analyzed 55 patients with HCC. Baseline cfDNA was dichotomized at the median to evaluate associations with overall survival (OS) and treatment response (objective response rate [ORR], disease control rate [DCR], and DR). In a discovery cohort (n = 17), targeted mutation and methylation profiling on baseline and progression cfDNA was performed. Candidate CpGs were identified by intersecting baseline differential methylation with longitudinal changes, and top hits were validated in an independent cohort (n = 32).
resultsHigh-cfDNA independently predicted shorter OS (median 13.0 vs. 33.1 months; p = 0.0015) but not ORR, DCR, or DR. Mutation analysis yielded no predictive markers. Integrative methylation profiling identified a locus in CD86 (Chr3:121,795,811) (area under the curve [AUC], 0.903 in discovery); baseline methylation here was associated with DR with an AUC of 0.806 in validation. Patients with high CD86 methylation exhibited higher DR rates and prolonged progression-free survival. Multivariate logistic regression analysis confirmed that high CD86 methylation was independently associated with DR (odds ratio: 6.96, 95% confidence interval: 1.70-28.50; p = 0.0071).
conclusionsBaseline cfDNA quantity and cfDNA-derived CD86 methylation were associated with clinical outcomes in patients with unresectable HCC treated with atezolizumab-bevacizumab. Prospective validation in larger independent cohorts is warranted before clinical implementation.
Indexed as
Identifiers
42406326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.